Form 4: Repligen CPO Brian Douglass Executes Tax Withholding

Repligen Corporation Chief Product Officer Brian Douglass reported the withholding of 334 shares to satisfy tax obligations.

Summary

• Brian Douglass, Chief Product Officer at Repligen Corporation, disposed of 334 shares of common stock.
• The transaction occurred on May 7, 2026, at a price of $126.43 per share.
• The disposal was executed to satisfy tax withholding obligations related to the vesting of restricted stock units.
• Following this transaction, the reporting person maintains beneficial ownership of 7,985 shares of Repligen common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it is a routine administrative transaction required for tax compliance.

Positives

• The transaction is routine and related to tax obligations rather than a discretionary sale of equity.
• The reporting person retains a significant stake of 7,985 shares, indicating continued alignment with shareholder interests.

Negatives

• The transaction represents a reduction in the direct shareholding of a key executive.

Risks

• None identified; this is a standard administrative transaction.

Future Outlook

Not applicable as this is a retrospective disclosure of a specific transaction.

Industry Context

StockSavvy.ai notes that tax-related share withholding is a standard practice for executives in the bioprocessing and life sciences sector, reflecting the vesting of equity-based compensation rather than a change in market sentiment.

Comparison to Industry Standards

• The transaction aligns with standard corporate governance practices for executive compensation in the life sciences industry.
• The use of 'sell-to-cover' for tax obligations is consistent with practices at peer companies like Danaher or Thermo Fisher.

Stakeholder Impact

• Minimal impact on shareholders as the transaction is a standard tax-related equity adjustment.

Key Dates

Keywords

Repligen, RGEN, Insider Trading, Form 4, Tax Withholding, Bioprocessing